Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sureshkumar Mulampurath Achuthan Pillai"'
Autor:
Hareesh B. Nair, Uday P. Pratap, Kumaraguruparan Ramasamy, Prabhakar Pitta Venkata, Kristin A. Altwegg, Suryavathi Viswanadhapalli, Philip T. Valente, Xiaonan Li, Ratna K. Vadlamudi, Junhao Liu, Weiwei Tang, Sureshkumar Mulampurath Achuthan Pillai, Rajeshwar Rao Tekmal, Swapna Konda, Gangadhara R. Sareddy, Edward R. Kost, Behnam Ebrahimi, Zexuan Liu, Bindu Santhamma, Logan Blankenship
Publikováno v:
Cell Death Discovery
Cell Death Discovery, Vol 7, Iss 1, Pp 1-10 (2021)
Cell Death Discovery, Vol 7, Iss 1, Pp 1-10 (2021)
Endometrial cancer (EC) is the fourth most common cancer in women. Advanced-stage EC has limited treatment options with a poor prognosis. There is an unmet need for the identification of actionable drivers for the development of targeted therapies in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e218fa042859bacd99fe622b29efa76
http://europepmc.org/articles/PMC8367961
http://europepmc.org/articles/PMC8367961
Autor:
Takayoshi Suzuki, Gabrielle Gray, Rajeshwar Rao Tekmal, Yi He, Srinath Palakurthi, Sureshkumar Mulampurath Achuthan Pillai, Prabhakar Pitta Venkata, Zhao Lai, Junhao Liu, Edward R. Kost, Salvador Alejo, Suryavathi Viswanadhapalli, Ilanna Loeffel, Gangadhara R. Sareddy, Yi Zou, Bridgitte E. Palacios, Ratna K. Vadlamudi, Uday P. Pratap, Yihong Chen
Publikováno v:
Cancer letters. 524
Endometrial cancer (EC) often exhibit aberrant activation of PI3K/Akt/mTOR signaling and targeted therapies using mTOR inhibitors showed limited success. The epigenetic modifier, lysine-specific histone demethylase-1A (KDM1A/LSD1) is overexpressed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70ad2d9424beea8ece843b299524d4ec
https://pubmed.ncbi.nlm.nih.gov/34673129
https://pubmed.ncbi.nlm.nih.gov/34673129
Autor:
Mauricio La Rosa, Maged M. Costantine, Sureshkumar Mulampurath Achuthan Pillai, Egle Bytautiene Prewit
Publikováno v:
American Journal of Obstetrics and Gynecology. 224:S613-S614
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3ddc86c5df3a3d1ab6fa58d94970f00
https://doi.org/10.1016/j.ajog.2020.12.1014
https://doi.org/10.1016/j.ajog.2020.12.1014
Autor:
Rajeshwar Rao Tekmal, Weiwei Tang, Xiaonan Li, GR Sareddy, Kristin A. Altwegg, Suryavathi Viswanadhapalli, Kumaraguruparan Ramasamy, Zexuan Liu, Ratna K. Vadlamudi, Junhao Liu, Sureshkumar Mulampurath Achuthan Pillai, Logan Blankenship, Swapna Konda, Behnam Ebrahimi, Prabhakar P. Vekata, Bindu Santhamma, Uday P. Pratap, Hareesh B. Nair, Edward R. Kost
Publikováno v:
Cancer Research. 81:1253-1253
Background: Endometrial cancer (EC) is the fourth most common cancer in women. Approximately 80% of EC belong to the endometroid-EC subtype and are driven by estrogen signaling. Advanced-stage EC has limited treatment options with poor prognosis. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee40799d98674db20c7381c829e9c824
https://doi.org/10.1158/1538-7445.am2021-1253
https://doi.org/10.1158/1538-7445.am2021-1253
Autor:
Christos Fountzilas, Sureshkumar Mulampurath Achuthan Pillai, John Sarantopoulos, Devalingam Mahalingam, Joel E. Michalek, Michael Pollak, Ian M. Thompson, Salih Hanni, John G. Kuhn
Publikováno v:
Cancer Research. 78:3269-3269
Background: ADT results in metabolic syndrome, characterized by hyperinsulinemia, insulin resistance and obesity. The hyperinsulinemia may result in ADT resistance; therefore preventing metabolic syndrome could have a therapeutic impact on PCa. Metfo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::deff8f5d896d318f4d3e6de17db494b8
https://doi.org/10.1158/1538-7445.am2018-3269
https://doi.org/10.1158/1538-7445.am2018-3269
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.